Colon cancer breakthrough – combo therapy halts cell growth
By Rob Clancy, staff writer. Reviewed by Professor Ron Firestein
A colon cancer breakthrough at Hudson Institute has shown that combining two types of drugs targeting gene expression stops cancer proliferation.
Australia has one of the highest rates of colon cancer (also known as bowel cancer or colorectal cancer) in the world – 1 in 13 Australians will develop the disease in their lifetime – and it is the nation’s second deadliest cancer.
Now pre-clinical research has shown that disabling two proteins together robs cancer cells of their ability to express genes necessary for their growth and spread.
How cell transcription machinery works
The research, published in the journal Molecular Cell, marks a significant step in the understanding of how the transcription machinery process works in cancer cells.
Associate Professor Ron Firestein, Head of the Cancer Centre at the Hudson Institute of Medical Research, believes this colon cancer breakthrough could have far-reaching impacts for not just bowel cancer but other cancer types as well.
“In total, this work has found the ‘two brake pads’ that when pressed together stops cancer gene expression and growth,” A Prof Firestein said.
“Importantly, the two drugs we tested together are already in clinical and pre-clinical development, offering an expedient path for translating these findings to patients.”
“This research goes beyond bowel cancer and shows that cancer cells are fundamentally evasive and utilise multiple paths to express the genes that they require for growth and spread.
Two classes of proteins drive colon cancer cells
“Specifically, we show that two classes of proteins, CDK8/19 and BET proteins, work together to drive gene expression in cancer cells.
“Remarkably, when cancer cells were treated with inhibitors targeting both proteins, they could no longer express the genes required for malignancy.
Collaborators | Monash Health, Monash University
This research was supported by | NHMRC
Journal | Molecular Cell
Title | MED12 and BRD4 cooperate to sustain cancer growth upon loss of mediator kinase
In this article
About Hudson Institute
Hudson Institute’ s research programs deliver in five areas of medical need – inflammation, cancer, reproductive health, newborn health, and hormones and health. More
Hudson News
Get the inside view on discoveries and patient stories
“Thank you Hudson Institute researchers. Your work brings such hope to all women with ovarian cancer knowing that potentially women in the future won't have to go through what we have!”